

# Tamam Bakchoul

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5648969/publications.pdf>

Version: 2024-02-01

65  
papers

2,249  
citations

279487

23  
h-index

243296

44  
g-index

70  
all docs

70  
docs citations

70  
times ranked

3906  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants. <i>Clinical Infectious Diseases</i> , 2023, 76, e240-e249.	2.9	11
2	Multicentre evaluation of 5B9, a monoclonal anti- $\text{PF4}$ /heparin IgG mimicking human HIT antibodies, as an internal quality control in HIT functional assays: Communication from the ISTH SSC Subcommittee on Platelet Immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 252-259.	1.9	5
3	Antibody-mediated procoagulant platelet formation in COVID-19 is AKT dependent. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 387-398.	1.9	18
4	Upregulation of cAMP prevents antibody-mediated thrombus formation in COVID-19. <i>Blood Advances</i> , 2022, 6, 248-258.	2.5	19
5	Immune-Mediated Platelet Activation in COVID-19 and Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Frontiers in Immunology</i> , 2022, 13, 837629.	2.2	14
6	Diagnosis of Platelet Function Disorders: A Challenge for Laboratories. <i>Hamostaseologie</i> , 2022, 42, 036-045.	0.9	5
7	Assessment and Monitoring of Coagulation in Patients with COVID-19: A Review of Current Literature. <i>Hamostaseologie</i> , 2022, 42, 409-419.	0.9	3
8	Anti- $\text{PF4}$ testing for vaccine-induced immune thrombocytopenia and thrombosis (VITT): Results from a NEQAS, ECAT and SSC collaborative exercise in 385 centers worldwide. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1875-1879.	1.9	6
9	The interaction between anti- $\text{PF4}$ antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia. <i>Blood</i> , 2022, 139, 3430-3438.	0.6	19
10	SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. <i>Nature Immunology</i> , 2021, 22, 74-85.	7.0	490
11	Antibody-induced procoagulant platelets in severe COVID-19 infection. <i>Blood</i> , 2021, 137, 1061-1071.	0.6	162
12	Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients. <i>MSphere</i> , 2021, 6, .	1.3	19
13	Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. <i>Nature Communications</i> , 2021, 12, 1152.	5.8	71
14	Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management. <i>Journal of Clinical Medicine</i> , 2021, 10, 789.	1.0	38
15	Antibody-mediated platelet activation in COVID-19: A coincidence or a new mechanism of the dysregulated coagulation system?. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1171-1173.	1.9	6
16	Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia. <i>Haematologica</i> , 2021, 106, 2170-2179.	1.7	101
17	Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1585-1588.	1.9	127
18	Immune response to SARS-CoV-2 variants of concern in vaccinated individuals. <i>Nature Communications</i> , 2021, 12, 3109.	5.8	118

#	ARTICLE	IF	CITATIONS
19	The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia. <i>Blood</i> , 2021, 138, 992-996.	0.6	37
20	Platelet Activation and Plasma Levels of Furin Are Associated With Prognosis of Patients With Coronary Artery Disease and COVID-19. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2080-2096.	1.1	21
21	The SSC platelet immunology register of VITT and VIITP: Toward standardization of laboratory and clinical parameters. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2094-2095.	1.9	4
22	Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2082-2088.	1.9	14
23	No Correlation between Anti-PF4 and Anti-SARS-CoV-2 Antibodies after ChAdOx1 nCoV-19 Vaccination. <i>New England Journal of Medicine</i> , 2021, 385, 1334-1336.	13.9	19
24	Blood donor-derived buffy coat to produce platelets in vitro. <i>Vox Sanguinis</i> , 2020, 115, 94-102.	0.7	3
25	Autoantibody-mediated desialylation impairs human thrombopoiesis and platelet lifespan. <i>Haematologica</i> , 2020, 106, 196-207.	1.7	38
26	Defibrotide for the Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 2 Pediatric Patients. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 622-625.	0.6	13
27	Real-life evaluation of an automated immunoassay for diagnosis of heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2020, 196, 400-403.	0.8	5
28	Fetal/neonatal alloimmune thrombocytopenia: a systematic review of impact of HLA-DRB3*01:01 on fetal/neonatal outcome. <i>Blood Advances</i> , 2020, 4, 3368-3377.	2.5	11
29	Red blood cell-derived semaphorin 7A promotes thrombo-inflammation in myocardial ischemia-reperfusion injury through platelet GPIb. <i>Nature Communications</i> , 2020, 11, 1315.	5.8	39
30	Feasibility of precise and reliable glucose quantification in human whole blood samples by 1 tesla benchtop NMR. <i>NMR in Biomedicine</i> , 2020, 33, e4358.	1.6	3
31	Heparin-induced thrombocytopenia: Diagnostic challenges in intensive care patients especially with extracorporeal circulation. <i>Thrombosis Research</i> , 2020, 188, 52-60.	0.8	11
32	Beta-Glycerophosphate-Induced ORAI1 Expression and Store Operated Ca <sup>2+</sup> Entry in Megakaryocytes. <i>Scientific Reports</i> , 2020, 10, 1728.	1.6	9
33	Apoptosis Inhibition: A Promising Approach for Cold Storage of Apheresis Platelet Concentrates. <i>Hamostaseologie</i> , 2020, 40, .	0.9	0
34	Flow Cytometric Assessment of AKT Signaling in Platelet Activation: An Alternative Diagnostic Tool for Small Volumes of Blood. <i>Hamostaseologie</i> , 2020, 40, .	0.9	0
35	Pathophysiology of Autoimmune Thrombocytopenia: Current Insight with a Focus on Thrombopoiesis. <i>Hamostaseologie</i> , 2019, 39, 227-237.	0.9	26
36	Evaluation of a flow cytometer-based functional assay using platelet-rich plasma in the diagnosis of heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2019, 180, 55-61.	0.8	10

#	ARTICLE	IF	CITATIONS
37	Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia. <i>Haematologica</i> , 2019, 104, 1237-1243.	1.7	26
38	Cold storage of platelets in additive solution: the impact of residual plasma in apheresis platelet concentrates. <i>Haematologica</i> , 2019, 104, 207-214.	1.7	37
39	Maternal $\alpha$ HPA-1a antibody level and its role in predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic review. <i>Vox Sanguinis</i> , 2019, 114, 79-94.	0.7	33
40	Screening and evaluation of potential recipients and donors for living donor uterus transplantation: results from a single-center observational study. <i>Fertility and Sterility</i> , 2019, 111, 186-193.	0.5	29
41	An international external quality assessment for laboratory diagnosis of heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 525-531.	1.9	23
42	Autoantibody Mediated Desialylation Impairs Human Thrombopoiesis and Platelet Life Span. <i>Blood</i> , 2019, 134, 2346-2346.	0.6	1
43	Drug-associated thrombocytopenia. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 576-583.	0.9	75
44	Anti-Glycoprotein V Autoantibodies in Patients with Immune Thrombocytopenia: Regularly Detectable and Functionally Relevant. <i>Blood</i> , 2018, 132, 1141-1141.	0.6	0
45	Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT): Guidance to Reduce the Risk of Intracranial Bleeding. <i>Blood</i> , 2018, 132, 4717-4717.	0.6	1
46	Evaluation of a diagnostic algorithm for Heparin-Induced Thrombocytopenia. <i>Thrombosis Research</i> , 2017, 152, 77-81.	0.8	7
47	Thrombozytopenie bei ITP. <i>Hamostaseologie</i> , 2016, 36, 187-194.	0.9	10
48	Clinical and laboratory tests for the diagnosis of heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2016, 116, 823-834.	1.8	41
49	Heparin-induced thrombocytopenia in 2017 and beyond. <i>Thrombosis and Haemostasis</i> , 2016, 116, 781-782.	1.8	5
50	Assessment of human platelet survival in the NOD/SCID mouse model: technical considerations. <i>Transfusion</i> , 2016, 56, 1370-1376.	0.8	9
51	Safe bridging to warfarin in heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2016, 144, 226-228.	0.8	0
52	Antiendothelial $\alpha$ 23 Antibodies Are a Major Cause of Intracranial Bleeding in Fetal/Neonatal Alloimmune Thrombocytopenia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1517-1524.	1.1	79
53	An update on heparin-induced thrombocytopenia: diagnosis and management. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 787-797.	1.0	10
54	Multicentric validation of a rapid assay for heparin-induced thrombocytopenia with different specimen types. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 6-9.	0.5	9

#	ARTICLE	IF	CITATIONS
55	Management of infants born with severe neonatal alloimmune thrombocytopenia: the role of platelet transfusions and intravenous immunoglobulin. <i>Transfusion</i> , 2014, 54, 640-645.	0.8	34
56	Evaluation of automated immunoassays in the diagnosis of heparin induced thrombocytopenia. <i>Thrombosis Research</i> , 2013, 131, e85-e90.	0.8	69
57	The implementation of surface plasmon resonance technique in monitoring pregnancies with expected fetal and neonatal alloimmune thrombocytopenia. <i>Transfusion</i> , 2013, 53, 2078-2085.	0.8	17
58	Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis. <i>Blood</i> , 2013, 121, 2821-2827.	0.6	64
59	Glycosylation of autoantibodies: Insights into the mechanisms of immune thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1259-1266.	1.8	19
60	Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT). <i>Thrombosis Research</i> , 2011, 127, 345-348.	0.8	45
61	Evaluation of a new nanoparticle-based lateral-flow immunoassay for the exclusion of heparin-induced thrombocytopenia (HIT). <i>Thrombosis and Haemostasis</i> , 2011, 106, 1197-1202.	1.8	44
62	Low avidity anti-HPA-1a alloantibodies are capable of antigen-positive platelet destruction in the NOD/SCID mouse model of alloimmune thrombocytopenia. <i>Transfusion</i> , 2011, 51, 2455-2461.	0.8	36
63	GP IIb/IIIa-Dependent Complement Activation Is Common In Patients with Immune Thrombocytopenic Purpura.. <i>Blood</i> , 2010, 116, 1430-1430.	0.6	0
64	Rapid detection of HPA-1 alloantibodies by platelet antigens immobilized onto microbeads. <i>Transfusion</i> , 2007, 47, 1363-1368.	0.8	20
65	Acquired immune thrombocytopenia: an update on pathophysiology, diagnosis and management. <i>Annals of Blood</i> , 0, 3, 45-45.	0.4	1